Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$84.08MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Moatazedi
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 353
- Beta
- 1.43
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.45
Financials
Revenue
$84.08M+3538.4%Net Income
$-8.05MEBITDA
$-4.03MFree Cash Flow
$-2.36MEPS (diluted)
$-0.12Shares Outstanding (diluted)
65.93M+298.9%Operating Expenses
$58.94MCash & Debt
$45.17MReturn of Capital
$0.00Revenue by Segment (annual)
$297.18MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $297.18M | $-51.64M | $-0.80 |
| 2024 | $266.27M | $-50.42M | $-0.81 |
| 2023 | $202.09M | $-61.69M | $-1.08 |
| 2022 | $148.62M | $-74.41M | $-1.33 |
| 2021 | $99.67M | $-46.81M | $-0.94 |
| 2020 | $56.54M | $-163.01M | $-4.83 |
| 2019 | $34.92M | $-90.03M | $-3.19 |
| 2018 | $0.00 | $-46.87M | $-1.92 |
| 2017 | $0.00 | $-4.48M | $-0.19 |
| 2016 | $0.00 | $-20.07M | $-1.08 |
| 2015 | $0.00 | $-31.11M | $-1.67 |
Valuation
EOLShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
87-13.33%Social Signal Score
Mentions (3)
- Newsbenzinga.com·3d ago·Negative
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug The U.S. Food and Drug Administration's Office of Prescription Drug Promotion in September issued a warning letter to Evolus Inc. (NASDAQ:EOLS) regarding misleading Instagram promotional posts for its injectable prescription drug, Jeuveau (prabotulinumtoxinA-xvfs).
View source ↗ - Newszacks.com·39d ago·Positive
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsseekingalpha.com·56d ago·Neutral
Evolus: The Injectable Platform Is Becoming The Real Moat Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and recurring revenue. Q2 2026 results showed 21% revenue growth, positive adjusted EBITDA, and raised guidance, with management projecting 2028 revenue of $450M–$500M and EBITDA margins of 13–15%. Evolus trades at a forward EV/Sales of 1.86, a 50% discount to sector median, but requires margin
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.05 per share
Typical surprise -26.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.01 vs $-0.03beat
- Mon, May 4$-0.10 vs $-0.14beat
- Tue, Mar 3$0.04 vs $0.06miss
- Wed, Nov 5$-0.14 vs $-0.19beat
- Tue, Aug 5$-0.24 vs $-0.09miss
- Wed, May 7$-0.18 vs $-0.10miss
Estimates and results for EOLS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EOLS officers and directors.
- Bought
- $393k
- Sold
- $14.8m
2 trades
41 trades
- Moatazedi Davidsold
- Avelar Ruisold
- Moatazedi Davidsold
- Moatazedi Davidsold
- Avelar Ruisold
- Moatazedi Davidsold
- Avelar Ruisold
- Yamagishi-dressler Tomokosold
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EOLS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.